A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes

Azam Doustmohammadian, Ahmad Nezhadisalami, Fahimeh Safarnezhad Tameshke, Nima Motamed, Mansooreh Maadi, Mohammad Farahmand, Masoudreza Sohrabi, Cain C.T. Clark, Hossein Ajdarkosh, Amir Hossein Faraji, Mehdi Nikkhah, Elham Sobhrakhshankhah, Ramin Ebrahimi, Farhad Zamani*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    5 Citations (SciVal)
    Original languageEnglish
    Article number937554
    JournalFrontiers in Medicine
    Volume9
    DOIs
    Publication statusPublished (VoR) - 28 Jul 2022

    Funding

    This work was funded by the Gastrointestinal and liver Diseases Research Center (GILDRC), Iran University of Medical Sciences (IUMS) (grant no. 97-3-30-13227).

    FundersFunder number
    Iran University of Medical Sciences97-3-30-13227
    Gastrointestinal and Liver Diseases Research Center

      Keywords

      • clinical trial design
      • fibrosis scores
      • liver enzymes
      • NAFLD
      • sitagliptin

      Fingerprint

      Dive into the research topics of 'A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes'. Together they form a unique fingerprint.

      Cite this